RxDoctor Payments Data

Gary Keilson, MD

Neurology · Worcester, MANPI 1508857707

Payments from drug & device makers

$312,273in general payments, 2019–2025

Across 69 payments — averaging $4525.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$273K
  • Roche Products Limited$39K
  • Lilly USA, LLC$89
  • Biogen$39
  • Lundbeck LLC$35
  • AbbVie$31
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$312,273 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$171,574
Medicare patients
491
Services billed
12,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate87$114,368
AubagioTeriflunomide12$110,314
CopaxoneGlatiramer Acetate17$96,097
Glatiramer Acetate32$76,882
GlatopaGlatiramer Acetate36$71,997
Teriflunomide50$55,604
UbrelvyUbrogepant50$51,430
Aimovig AutoinjectorErenumab-Aooe52$40,799
Dalfampridine ErDalfampridine36$31,277
Emgality PenGalcanezumab-Gnlm35$25,544
Dimethyl Fumarate24$16,718
ZonisadeZonisamide16$12,654
Levetiracetam306$10,792
Ajovy AutoinjectorFremanezumab-Vfrm13$9,294
Memantine Hcl219$8,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$31$51,43050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →